Incretin-Based Drugs Market Growth Surge to Reach US$ 42.42 Billion by 2033 | Competitive Positioning & Late-Stage Drug Pipelines

Incretin-Based Drugs Market reached US$ 26.69 Billion in 2024 and is expected to reach US$ 42.42 Billion by 2033, growing at a CAGR of 5.6% during the forecast period 2025-2033

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/incretin-based-drugs-market?kb

United States - Recent Industry Developments

✅ Nov 2025: Eli Lilly expanded the supply of tirzepatide-based therapies due to rising demand in obesity and diabetes management.

✅ Oct 2025: Pfizer initiated late-stage clinical trials for dual incretin receptor agonists targeting improved glycemic and weight control.

✅ Sep 2025: The FDA introduced fast-track review policies to accelerate approval pathways for next-generation incretin drugs.

Japan - Recent Industry Developments

✅ Nov 2025: Takeda Pharmaceuticals launched new once-weekly GLP-1 agonists to improve treatment adherence among diabetic patients.

✅ Oct 2025: A collaboration between Japanese universities and pharma companies advanced research on oral incretin-based therapies.

✅ Sep 2025: Japan's health agencies updated national diabetes care guidelines to include combination incretin therapy.

GCC - Recent Industry Developments

✅ Nov 2025: Novo Nordisk partnered with Saudi healthcare institutions to expand access to GLP-1 drugs for type-2 diabetes and obesity.

✅ Oct 2025: UAE hospitals adopted AI-based patient monitoring platforms integrating incretin therapy for metabolic disorders.

✅ Sep 2025: GCC governments introduced reimbursement support programs to boost adoption of next-gen incretin medications.

List of Top Key Player:

Eli Lilly and Company, Novo Nordisk, Merck & Co., Inc., AstraZeneca, Boehringer Ingelheim, Inc., Sanofi, Takeda Pharmaceutical Company Limited, Novartis AG, and Bristol-Myers Squibb Company

Latest M&A and partnering

Recent dealmaking is concentrated in obesity and next‐gen incretin platforms rather than classic DPP‐4s.

1. Pfizer agreed to acquire Metsera (Sept 2025) and its next‐generation obesity portfolio, which includes incretin‐based and related peptide assets such as MET‐097i with weekly or monthly dosing; the deal strengthens Pfizer's late‐entry obesity pipeline against Novo Nordisk and Eli Lilly.​

2. Obesity/incretin M&A and licensing has accelerated since 2023, exemplified by Roche's USD 3.1 billion purchase of Carmot Therapeutics (multi‐incretin pipeline) and other large licensing deals pairing GLP‐1 with amylin and additional mechanisms.​

3. Analysts highlight that board‐level KPIs now explicitly track the share of revenue and R&D mix tied to GLP‐1/incretin combinations, with expectations of intensified BD/M&A around metabolic platforms, delivery tech, and data assets through 2026.

Forecast Projection:

The Global Incretin-Based Drugs Market is poised for significant growth between 2025 and 2033. In 2024, the market maintained a steady upward trajectory, and with strategic initiatives by leading players accelerating adoption, the market is expected to soar throughout the forecast period. Companies leveraging these trends are well-positioned to capture emerging opportunities and maximize revenue potential.

Market Intelligence Research Process:

The Global Incretin-Based Drugs Market research report by DataM Intelligence combines primary and secondary data to deliver deep, actionable insights. It examines the full spectrum of factors shaping the industry, from government regulations and market conditions to competitive dynamics, historical trends, technological breakthroughs, upcoming innovations, and potential challenges. This comprehensive analysis not only highlights growth prospects but also identifies barriers, equipping businesses to navigate market volatility and capitalize on emerging opportunities.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=incretin-based-drugs-market?kb

Key Segments:

By Drug Class: (Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Analogues)

By Route of Administration; (Oral, Injectable)

By Distribution Channel: (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Global Growth Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1 - Market Overview: Kickstarts the report with a comprehensive snapshot of the Global Incretin-Based Drugs Market, summarizing key segments by region, product type, and application. Highlights include market size, segment growth potential, and short- & long-term industry outlook.

Chapter 2 - Emerging Trends: Uncovers the game-changing trends and high-impact innovations shaping the future of the industry.

Chapter 3 - Competitive Landscape: Offers a deep dive into market competition, detailing revenue shares, strategic initiatives, and recent mergers & acquisitions.

Chapter 4 - Top Player Profiles: Features detailed company profiles, covering revenue, profit margins, product lines, and major milestones for leading market players.

Chapters 5 & 6 - Regional & Country Analysis: Breaks down revenue performance across global regions, providing insights on market sizes, opportunities, and growth prospects worldwide.

Chapter 7 - Segmentation Analysis: Explores market segmentation by type, revealing high-potential categories and guiding businesses towards lucrative areas.

Chapter 8 - Application Insights: Examines downstream markets and identifies promising sectors for expansion, showing how different applications are driving growth.

Chapter 9 - Supply Chain Mapping: Maps the entire industry supply chain, highlighting upstream and downstream activities for a holistic market perspective.

Chapter 10 - Key Takeaways: Concludes with critical insights and actionable strategies, equipping stakeholders to make informed decisions and stay ahead in the market.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/incretin-based-drugs-market?kb

FAQ's

Q1: What is the current size of the Global Incretin-Based Drugs Market and its future potential?

A: The Global Incretin-Based Drugs Market was valued at US$ 26.69 Billion in 2024 and is projected to surge to US$ 42.42 Billion by 2033

Q2: How fast is the Global Incretin-Based Drugs Market expected to grow in the coming years?

A: The market is forecast to expand at a robust CAGR of 5.6% between 2025 and 2033

Q3: Which regions are dominating the Global Incretin-Based Drugs Market and which are fastest-growing?

A: Key markets include North America, Europe, and Asia-Pacific, led by the U.S., Japan, China, and Germany.

Request 2 Days Free Trials with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?kb

Key recently approved or advanced incretin drugs

Most recent "new" products are label expansions and new combinations of existing incretins, plus several late‐stage pipeline assets.

1. Semaglutide (Novo Nordisk) continues to receive supplemental approvals: in late 2025, the FDA approved an sNDA extending oral semaglutide (Rybelsus 7 mg and 14 mg) to additional type 2 diabetes populations, and several further GLP‐1 decisions (for Ozempic and Wegovy in PAD and HFpEF with obesity) are expected in 2025.​

2. Tirzepatide (Eli Lilly), a dual GIP/GLP‐1 agonist, is now approved in the U.S. and EU for both type 2 diabetes and chronic weight management, delivering mean weight loss of at least 20% in key trials, positioning it as a benchmark "next‐gen" incretin.​

The development pipeline includes multiple dual and triple incretin mimetics:

1. Amycretin (Novo Nordisk) - an amylin/GLP‐1‐type agent that showed acceptable tolerability in a phase 1 trial reported in October 2024.​

2. Multiple oral GLP‐1 and oral multi‐incretin candidates in phase 2-3, as summarized in recent obesity‐pipeline reviews.

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Related Reports:

GLP-1 Agonists: https://www.datamintelligence.com/download-sample/glucagon-like-peptide-1-analogues-market?kb

Diabetes Drugs Market: https://www.datamintelligence.com/download-sample/diabetes-drugs-market?kb

Type 2 Diabetes Market: https://www.datamintelligence.com/download-sample/diabetes-drugs-market?kb

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

This release was published on openPR.